Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis

Abstract Background Due to cardiotoxicity concerns, the concurrent use of epirubicin and trastuzumab has not been fully studied. This study aimed to examine the cardiotoxicity and pathological complete response (pCR) rate associated with the concurrent regimens in patients with human epidermal growt...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Ming‐Han Yang, Chiun‐Sheng Huang, Dwan‐Ying Chang, Fu‐Chang Hu, Shu‐Min Huang, Po‐Hsiang Huang, I‐Chun Chen, Tom Wei‐Wu Chen, Ching‐Hung Lin, Yen‐Shen Lu
Format:	Artigo
Sprog:	Inglês
Udgivet:	Wiley 2024-07-01
Serier:	Cancer Medicine
Fag:	cardiotoxicity early breast cancer epirubicin human epidermal growth factor receptor 2 trastuzumab
Online adgang:	https://doi.org/10.1002/cam4.70005
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!